Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Target Price
The average target price of 2171.HK is 24 and suggests 48% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell